FSA Wealth Management LLC Has $224,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

FSA Wealth Management LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 5.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,550 shares of the company’s stock after selling 96 shares during the period. FSA Wealth Management LLC’s holdings in Johnson & Johnson were worth $224,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of JNJ. J. Safra Sarasin Holding AG raised its stake in Johnson & Johnson by 3.1% in the 4th quarter. J. Safra Sarasin Holding AG now owns 321,646 shares of the company’s stock valued at $46,516,000 after acquiring an additional 9,541 shares during the period. Optivise Advisory Services LLC grew its position in Johnson & Johnson by 15.7% in the fourth quarter. Optivise Advisory Services LLC now owns 2,096 shares of the company’s stock worth $303,000 after acquiring an additional 284 shares in the last quarter. Select Asset Management & Trust lifted its stake in Johnson & Johnson by 164.8% during the fourth quarter. Select Asset Management & Trust now owns 3,535 shares of the company’s stock worth $511,000 after purchasing an additional 2,200 shares during the last quarter. Van Lanschot Kempen Investment Management N.V. boosted its stake in Johnson & Johnson by 11.3% in the fourth quarter. Van Lanschot Kempen Investment Management N.V. now owns 1,074,408 shares of the company’s stock worth $155,381,000 after buying an additional 109,286 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Johnson & Johnson by 71.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 158,825 shares of the company’s stock worth $22,969,000 after acquiring an additional 66,143 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research firms recently commented on JNJ. Raymond James dropped their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research report on Monday, April 14th. The Goldman Sachs Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Wells Fargo & Company lowered their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Bank of America reduced their target price on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday, April 10th. Finally, Morgan Stanley raised their target price on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 16th. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $171.82.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $157.00 on Tuesday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The firm has a 50 day moving average of $159.53 and a two-hundred day moving average of $154.93. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $378.35 billion, a PE ratio of 23.61, a P/E/G ratio of 2.56 and a beta of 0.49.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $21.89 billion during the quarter, compared to analysts’ expectations of $21.65 billion. On average, research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.31%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s dividend payout ratio (DPR) is 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.